Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
273
resultados
Última actualización
06/05/2026 [08:15:00]
Resultados 25 a 50 de 273
Resumen de: WO2026084225A1
The present invention relates to a method for screening a lysophagy activator by promoting ubiquitination, and a pharmaceutical composition that contains the lysophagy activator selected by the screening method, and thus can treat or prevent lysosomal regulatory disorders, such as lysosomal storage disorders, neurodegenerative diseases, diabetes, or cancers.
Resumen de: WO2026085524A1
Featured are methods and compositions for production of ovarian support cells. In particular, the disclosure features methods of culturing or producing ovarian support cells from pluripotent stem or progenitor cells. The ovarian support cells described herein may be used for various purposes, including the treatment of ovarian decline, infertility, and a wide array of other reproductive and gynecologic conditions, as well as for modeling particular components of the human reproductive system in order to identify and characterize new therapeutic interventions.
Resumen de: AU2024342922A1
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Resumen de: US20260110700A1
Provided are methods and kits for blood sample collection, protein extraction, and analysis of neuro biomarkers obtained from blood samples on dried blood drop cards.
Resumen de: WO2024200757A1
The present disclosure relates to methods of identifying and reducing anti-Fc epsilon Receptor I (FcεRI) immunoglobulins (Ig) associated with adverse reactions from plasma or a fraction thereof, formulations and uses of the anti-FcεRI Ig reduced plasma protein product thereof.
Resumen de: US20260110685A1
Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the quantitative expression values of the markers.
Resumen de: US20260109946A1
The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.
Resumen de: WO2026084453A1
The present invention relates to a drug delivery system capable of efficiently penetrating the blood-brain barrier (BBB). More specifically, the present invention relates to a drug delivery platform which fuses transthyretin (TTR) or a functional variant thereof with a peptide sequence comprising a certain amino acid sequence, and thus can be applied to a therapeutic agent for brain diseases and a diagnostic composition.
Resumen de: EP4729947A2
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.
Resumen de: EP4729538A2
0001 The present invention relates to Tau-binding antibodies and binding fragments thereof.
Resumen de: EP4729943A2
0001 Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).
Resumen de: WO2023238955A1
The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found that an Aβ peptide, or a sweet amino acid or an umami substance specifically binds to a type I taste receptor on the surface of a nerve cell to exert an agonist-like or antagonist-like action, thereby amplifying or suppressing a VGSC active current. Moreover, with the binding of an Aβ peptide or the like to a type I taste receptor, the amplification of a VGSC active current occurs, the overactivity of nerve cells causing epileptiform attack occurs, and a large number of substances, which can effectively suppress the amplification of the VGSC active current, among ligand substances that specifically bind to the type I taste receptor, can be found. The present invention provides: a type I taste receptor-specific ligand substance that can control the amplification or suppression of a VGSC active current; and a pharmaceutical composition for preventing or treating various neurodegenerative diseases, such as Alzheimer's disease (AD), due to the amplification of a VGSC active current caused by the binding of an Aβ peptide or the like to a type I taste receptor. Moreover, a method for using, as a target receptor, a type I taste receptor present in a nerve cell or the like to screen a ligand substance for controlling a VGSC or the like in the ce
Resumen de: CN121878225A
本发明涉及疾病诊断的即时检测领域，公开了基于酶促荧光硅纳米点的阿尔茨海默病标志物检测方法，包括利用磁性捕获探针富集目标标志物并形成酶标免疫夹心复合物；随后加入底物，利用酶促反应产生的抗坏血酸原位诱导生成荧光硅纳米点或抑制显色反应；通过采集反应体系的时间序列图像，利用HSV色彩空间转换及色度特征掩膜算法剔除干扰像素，计算反应动力学速率并结合标准曲线实现定量分析。通过引入碱性磷酸酶诱导的级联反应体系，利用酶解产物抗坏血酸原位生成荧光硅纳米点或调控TMB氧化还原状态，实现了对Tau蛋白和Aβ‑42蛋白的高灵敏度检测，进而提升了对低浓度阿尔茨海默病标志物的检测灵敏度。
Resumen de: CN121873230A
本发明属于免疫学领域，具体涉及一种识别Tau蛋白181位点磷酸化的单克隆抗体及其应用。所述的单克隆抗体制备时采用了针对Tau蛋白第181位磷酸化位点设计的抗原多肽，其具体序列为：PK(pT)PPC，其中(pT)表示磷酸化的氨基酸。所述单克隆抗体重链可变区氨基酸序列包括SEQ ID No.1所示的CDR1、SEQ ID No.2所示的CDR2和SEQ ID No.3所示的CDR3；所述轻链可变区氨基酸序列包括SEQ ID No.4所示的CDR1、SEQ ID No.5所示的CDR2和SEQ ID No.6所示的CDR3。该单克隆抗体可对磷酸化的Tau蛋白181位点进行高特异性、高灵敏度、高准确性检测。
Resumen de: CN121873240A
0001 本申请公开了一种MTBR‑tau243特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域，本申请提供了靶向MTBR‑tau243的抗体、检测MTBR‑tau243的化学发光试剂盒。本申请的抗体亲和力高、灵敏度高和生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域。本申请公开的试剂盒可以用于与MTBR‑tau243相关的疾病，例如阿尔茨海默症的辅助诊断。
Resumen de: CN121877500A
0001 本发明属于生物技术领域，具体涉及一种干血片样本的处理方法及其在脑健康指标检测中的应用。包括以下步骤：1)制备滤纸干血片；2)应用干血片洗脱液，对滤纸干血片进行洗脱，得到洗脱液；3)应用磁珠偶联血红蛋白抗体，去除洗脱液中的血红蛋白，得到检测样本。应用本发明干血片样本的处理方法，检测结果与直接检测血清的检测结果有良好的相关性；既降低了脑健康疾病检测的采样成本，又保证了检测的灵敏度和特异性。
Resumen de: US12534519B2
The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (FDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.
Resumen de: CN121873239A
本发明公开了一种抗人MBP单克隆抗体及其应用。所述单克隆抗体的重链可变区的互补决定区具有如SEQ ID NO.1‑3所示的氨基酸序列，轻链可变区的互补决定区具有如SEQ ID NO.4‑6所示的氨基酸序列。本发明通过化学合成多肽作为免疫原，对小鼠进行免疫，经细胞融合、筛选和亚克隆，获得高效分泌抗人MBP单克隆抗体的单克隆细胞系。本发明得到的抗体具有高特异性和高结合能力，能够有效从血清中靶向结合MBP蛋白，适用于血液中MBP蛋白的检测，从而对可能引起MBP蛋白浓度变化的神经损伤性疾病进行评价，为轻度创伤性脑损伤诊断提供更便利的条件。
Resumen de: CN121873188A
本发明公开了一种靶向去泛素化酶次磺酸的泛素探针及其制备方法和应用，其结构通式为：Biotin‑Ub‑W，其中Ub为泛素分子；W为亲核性弹头基团，其能够特异性地与DUBs活性位点半胱氨酸在氧化应激下形成的次磺酸(‑SOH)官能团发生共价反应，而对还原态半胱氨酸(‑SH)无反应性。本发明可用于在细胞或组织样品中特异性地标记、富集和鉴定受氧化还原调控的DUBs，为研究癌症、神经退行性疾病等相关疾病中的DUBs功能提供了前所未有的工具，并可用于筛选靶向该特定状态的药物。
Resumen de: WO2025054130A1
The present disclosure relates to enzymes capable of oxidizing betahydroxybutyrate (BHB). In aspects, the enzymes are engineered to optimize BHB activity. Engineered enzymes including amino acid substitutions, truncations, and sequence deletions are further provided. The disclosure further provides for use of enzymes described herein, for example, in test strips, BHB sensors, devices, and systems for detecting and measuring BHB concentration.
Resumen de: WO2025017127A1
Gp130 antigen-binding antibodies are disclosed which inhibit IL-6, IL-11, OSM, LIF, CNTF, CT-1 mediated signal and bind to the cytokine binding region. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, humanised antibodies and therapeutic methods using, the Gp130 antigen-binding antibodies.
Resumen de: CN121878216A
本发明属于预后预测技术领域，公开了基于血脂代谢标志物的肺癌免疫治疗的预后预测模型与应用。所述预后预测模型基于包括以下血脂代谢标志物构建得到：H4A2、LDPL、H4A1、H4PL、H4FC。本发明通过对肺癌患者免疫治疗前的外周血样本中血脂代谢物进行筛选，获得关键血脂代谢物标志物并建立起预后预测模型，利用该模型对患者的免疫治疗应答情况进行定量评估，可实现对疗效的精准预测。
Resumen de: US20260103494A1
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.
Resumen de: US20260103683A1
The disclosure relates to methods of generating at least one brain organoid-sufficient embryoid body or repairing at least one non-viable embryoid body, the method comprising incubating a population of induced pluripotent stem cells (iPSCs) in an embryoid body formation medium (EB FM), the EB FM comprising a culture medium, glutamine, recombinant human insulin, recombinant human transferrin, sodium selenite, and thermostable fibroblast growth factor 2 (FGF2). The disclosure further relates to methods of generating brain organoids from brain organoid-sufficient embryoid bodies and repairing embryoid bodies.
Nº publicación: US20260102478A1 16/04/2026
Solicitante:
LONGHORN VACCINES AND DIAGNOSTICS LLC [US]
Resumen de: US20260102478A1
The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and/or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and/or limbic predominant age-related TDP-43 encephalopathy (LATE).
BOPI
Sede Electrónica
